Medtronic: Americans Favor Quality Over Quantity in Pursuit of Longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer - it's about living their healthiest, best lives. While most want to live to 90-well past the average U.S. life expectancy of 77.5 years-nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology

With almost limitless health-related information at our fingertips and new healthcare innovations emerging daily, the American dream of extending both our lifespan and quality of life seems possible. However, only 39% of U.S. adults say they are taking preventative health measures such as screenings and regular medical check-ups, and less than a third (29%) are discussing longevity with their doctor. Only about half are focused on eating healthy (53%) and exercising (51%), despite diet and physical inactivity being leading contributors to chronic disease. And while 80% of Americans believe healthcare technology can help them live longer and healthier, only 18% are taking advantage of it.

"Health conditions can impact anyone at any age, so it's critical that we expand treatment options while also continuing to focus on prevention, so people can prioritize what's most important to them," said Dr. Laura Mauri, chief scientific, medical and regulatory officer at Medtronic. "The role of technology in helping people live longer and better lives is accelerating. It's enabling more personalized treatments, quicker recoveries and earlier diagnosis. What's more, every day researchers are discovering new technologies that continue to improve longevity and quality of life."

Perhaps the greatest power of technology is the range of options - and hope - it can give people regardless of their current health status. Already, healthcare technology is helping catch cancer before it progresses, treat pain with less oral medication and reduce the burden from chronic diseases.

"In my 19 years as a diabetic, I feel more supported by my diabetes technology than I ever have before," said Cameron Moore, who uses a Medtronic insulin pump with meal detection technology. "It means I worry less about complications so I can focus on the here and now of life with my family and enjoy each day to the fullest."

There are steps people can take today to take charge of their health and live their best life. Follow the acronym T.E.C.H.:

  • Talk to your doctor - Thanks to technologies like AI, there are new screening options that help detect and treat diseases earlier, including several common cancers and avoiding stroke. Ask your doctor what's available and how it might benefit you.
  • Explore treatment options - No one wants to be defined by their disease or ailment. Technology is helping reduce the burden of living with chronic conditions, like diabetes, high blood pressure, heart disease and neurologic disease and tech can also be an alternative to opioids for chronic pain.
  • Check your assumptions - Some people delay getting treatment due to worry about a long hospitalization or recovery time. Non-invasive or minimally invasive surgery procedures are resulting in fewer complications, shorter hospital stays and faster return to normal activities.
  • Honor your needs - Ensure your doctor knows what's important to you - attending a special event, continuing an activity you enjoy, or simplifying your care. This will help them develop a treatment plan with you that prioritizes your quality of life.

For more information on how Medtronic is advancing healthcare through technology and helping people live longer and healthier, visit Medtronic.com.

About the Consumer Perceptions of Longevity Survey
The survey was conducted by decision intelligence company Morning Consult among a nationally representative sample of 2,200 adults in the U.S. from February 15-20, 2024, with an unweighted margin of error of +/- 2 percentage points.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Erika Winkels
Public Relations
+1-763-526-8472

Ryan Weispfenning
Investor Relations
+1-763-505-4626

View additional multimedia and more ESG storytelling from Medtronic on 3blmedia.com.

Contact Info:
Spokesperson: Medtronic
Website: https://www.3blmedia.com/profiles/medtronic
Email: info@3blmedia.com

SOURCE: Medtronic



View the original press release on accesswire.com

News Provided by ACCESSWIRE via QuoteMedia

MDT
The Conversation (0)

Canadian Natural Resources Limited Announces 2024 First Quarter Results

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

-

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces Fourth Quarter And Year-End Results For 2023, Including Record Oil Royalty Production, Strong Leasing Activity And Increased Annual Dividend

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its fourth quarter (" Q4 2023 ") and year-end operating and financial results for the period ended December 31, 2023. PrairieSky is also pleased to announce a 4% increase in its annual dividend to $1.00 per common share ($0.25 per common share quarterly).

Fourth Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces 2023 Third Quarter Results

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its third quarter (" Q3 2023 ") results for the three-month period ended September 30, 2023.

Third Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, May 9, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health Announces First Quarter 2024 Results

  • First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis
  • Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis
  • GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million
  • Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13%
  • Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + Lomb
  • Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financial results and other key updates from the quarter

"We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA. Furthermore, all our business segments posted year-over-year revenue growth on both a reported and organic basis. I'm very proud of what our team has accomplished and we remain focused on continuing our momentum by advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Scientists working in a modern medical research laboratory.

Pathways to Commercializing Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialization strategy. Once a technology has been developed and proven, the organization must then embark on a process to commercialize it for revenue generation.

The strategy a company leverages to pursue commercialization is a crucial ingredient in building a successful and profitable venture.

Investors would do well to understand the distinctive process and strategies required to bring medtech solutions to market to help them make more informed investment decisions.

Keep reading...Show less

Medtronic: 'Pivotal Moment' in Women's Heart Health

Female-specific results from first-of-its-kind clinical trial

Teaching first graders takes a lot of energy. So when Julia Garcia started feeling worn out, teaching became extremely difficult

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

March 2024 Quarterly Activities Report

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to provide the market with an update on activities in the March 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.

Keep reading...Show less

Medtronic receives FDA approval for Inceptiv closed-loop spinal cord stimulator

Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×